Pharmaceutical

Lilly extends research pact with India firm

December 1, 2009
 IBJ Staff
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five years.
More

Lilly's Cymbalta wins new approval for anxiety disorder

November 30, 2009
J.K. Wall
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
More

Lilly stock droops after rival claims faster-acting impotence pill

November 18, 2009
 IBJ Staff
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly's Cialis.
More

Aarden Pharmaceuticals chose Indianapolis over San Diego for headquarters

November 14, 2009
 IBJ Staff
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided locating here would give Aarden a better chance of success.
More

Lilly to pay Utah $24 million to settle Zyprexa suit

November 11, 2009
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic drug Zyprexa.
More

Lilly to move 1,000 from Faris campus

October 26, 2009
J.K. Wall
As it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees to its corporate center by mid-2010.
More

Lilly needs to sell more Effient before Zyprexa loses patent protectionRestricted Content

October 24, 2009
J.K. Wall
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for the quarter.
More

Lilly settles Zyprexa case with S. Carolina for $45M

October 23, 2009
 IBJ Staff and Associated Press
South Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker Eli Lilly and Co. over the company's marketing of an anti-psychotic drug.
More

Eli Lilly CEO banking on new drug pipeline

October 22, 2009
Associated Press
CEO John Lechleiter says Lilly's pipeline has helped it rebound from significant patent losses three times during his 30-year career at the company. He's betting there will be a fourth.
More

Lilly, GE announce cancer diagnostic breakthrough

October 21, 2009
J.K. Wall
Eli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
More

Uncertainty over drug pipeline sends Lilly shares down

October 21, 2009
J.K. Wall
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products aren't likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
More

Lilly reports $942 million profit in third quarter

October 21, 2009
J.K. Wall
Excluding special items, Eli Lilly and Co.'s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog sales. Lilly's revenue rose 7 percent in the quarter over the same period of 2008, to $5.56 billion.
More

Medco plans to compare Plavix, Effient in study

October 20, 2009
 IBJ Staff and Associated Press
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
More

Endocyte receives $26M infusion from investors

October 16, 2009
West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company continue developing cancer-fighting drugs.
More

Lilly to pay Idaho $13M in drug settlement

October 14, 2009
 IBJ Staff and Associated Press
Idaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing of anti-psychotic drug Zyprexa.
More

Lilly to sell Lafayette plant to German firm

October 14, 2009
J.K. Wall
Nearly 700 workers will be offered severance, new jobs
More

Lilly settles Zyprexa suit with S. Carolina

October 7, 2009
 IBJ Staff
Eli Lilly and Co. has agreed to settle the State of South Carolina's lawsuit that claimed Lilly improperly marketed the antipsychotic drug Zyprexa, according to Bloomberg News.
More

Lilly's win in Evista patent case crucial, analyst says

September 24, 2009
Scott Olson
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.'s Evista marks a major victory for the company, says an analyst who closely follows the pharmaceutical industry.
More

Judge upholds Lilly's Evista patent

September 24, 2009
J.K. Wall
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced late yesterday.
More

Lilly agrees to settle more state Zyprexa suits

September 22, 2009
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
More

UPDATE: Pipeline challenges force Lilly restructuring moves

September 14, 2009
J.K. Wall
Since John Lechleiter was named CEO 18 months ago, he's bet that Eli Lilly and Co. could face down its looming patent challenges by launching innovative new medicines. Today's announcement of 5,500 job cuts by the end of 2011 and a restructuring of the company's business units ups the ante on that bet, while indicating that it isn't working yet.
More

Lilly reorganization to cut 5,500 positions over 2 years

September 14, 2009
J.K. Wall
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central Indiana. But with 13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
More

Local health care industry tries to capitalize on migraine headaches

September 12, 2009
J.K. Wall
Migraines cost American employers $20 billion a year in decreased worker productivity. Such a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
More

Lilly paid doctors to prescribe Zyprexa, notes say

September 8, 2009
 IBJ Staff
Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers' program in exchange for prescribing the antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.
More

AIT Laboratories leaps up Inc.'s list

August 24, 2009
 IBJ Staff
The Indianapolis-based forensics, clinical and pharmaceutical testing firm now ranks 598, up from 1,466 a year ago. The list is based on percentage of revenue growth.
More
Page  << 11 12 13 14 15 16 17 18 19 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Only half a million TV Viewers? And thats an increase? I knew Indycar was struggling but I didn't know it was that bad. Hell, if NASCAR hits 5 Million viewers everyone starts freaking out saying its going down hill. It has a long way to before Indycar even hits NASCAR's bad days.

  2. IU has been talking that line for years with no real progress even with the last Dean, Dr. Brater. Why will an outsider, Dr. Hess, make a difference? With no proof of additional resources (cash in the bank), and a concrete plan to move an academic model that has been outdated for decades with a faculty complacent with tenure and inertia, I can count on IU to remain the same during the tenure of Dr. Hess. One ought to look to Purdue and Notre Dame for change and innovation. It is just too bad that both of those schools do not have their own medical school. Competition might wake up IU. My guess is, that even with those additions to our State, IU will remain in its own little world squandering our State's tax dollars. Why would any donor want to contribute to IU with its track record? What is its strategy to deal with the physician shortage for our State? New leadership will not be enough for us to expect any change.

  3. How do you think the Bridges got approved? I spent a couple days researching PAC's and individual contributions to some city council members during that time. My printouts were inches thick on the two I concentrated on. Finally gave up. Was disgusted with all the donations, and who they were from. Would have taken me days and days to compile a complete list. Tried to give it to the Star reporter, but he thought it was all just fine. (and apparently he was treated well himself) He ended up being laid off or fired though. And then of course, there was land donated to the dad's club, or city, as a partial payoff. All done in the shining example of "charity." No, none of these contributions are a coincidence.

  4. I agree what kind of help or if any will be there for Dr. Ley's patients. I was a patient myself.

  5. What about the hundreds of patients who sought this doctor for the right reasons, to quit drugs. what option do these patients now have, experience horrible withdrawl or return to heroin?? those are the choices. what about the children of these former addicts who's parent(s) WILL not b able to maintain their job, for @ least 2 weeks.. There needs to b an emergency clinic opened for these patients.

ADVERTISEMENT